Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial

October 11, 2007 updated by: Bioheart, Inc.

A Phase II, Open-Label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)

To assess the efficacy and safety of MyoCell therapy on myocardial function in congestive heart failure patients, post-myocardial infarction

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Sunrise, Florida, United States, 33325
        • Richard Spencer

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • defined region of myocardial dysfunction related to previous MI (most recent MI at least 90 days prior to muscle biopsy involving the anterior, lateral, posterior or inferior walls, assessed by the presence of a Q-wave on the ECG & a large area of akinesia in the left ventricle, confirmed by either left ventricular angiography or echocardiography
  • NYHA class II or III
  • on optimal medical drug therapy for at least 2 months prior to study entry; defined by the most current ACC/AHA guidelines for the Evaluation & Management of chronic heart failure in the adult
  • >=18 and <=75 years old
  • need or feasibility for re-vascularization has been r/o by coronary or noninvasive stress testing within 30 days of screening, assessed using Dobutamine Stress Echocardiography
  • able to undergo surgical biopsy of the skeletal muscle & successful culture of the harvested myoblasts
  • well demarcated transmural myocardial scar (by echocardiography)Must have a minimum myocardial wall thickness of 5mm
  • must have been fitted w/ an ICD in place for the duration of the study at least 6 months prior to muscle biopsy
  • left ventricular EF at screening of >=20%, <=45% (by MUGA)
  • willing & able to give written informed consent
  • if female of childbearing potential, serum or urine pregnancy test must be negative w/in 2 weeks of study treatment

Exclusion Criteria:

  • MI w/in 90 days of the muscle biopsy
  • NYHA class I or IV
  • CABG w/in 6 months (180 days) prior to scheduled MyoCell implantation
  • PCI w/in 3 months (90 days) prior to scheduled MyoCell implantation
  • aortic valve replacement
  • heart failure secondary to valvular disease
  • left ventricular mural thrombus
  • known sensitivity to gentamicin sulfate and/or amphotericin-B
  • previous experimental angiogenic therapy and/or myocardial laser therapy
  • previous severe adverse reaction to nonionic radiocontrast agents
  • exposure to any investigational drug or procedure w/in 1 month prior to study entry or enrolled in any concurrent study that may confound the results of this study
  • serum creatinine >2.5 mg/dL or end stage renal disease
  • active infectious disease and/or known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM>IgG) and/or syphilis. If the panel includes antibodies to the HBV-cAg and HBV-sAg, then an expert will be consulted as to patient eligibility based on the patient's infectious status
  • females who are pregnant or nursing or of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
  • any illness which might affect patient's survival over the study follow up period or any illness which, in the investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
  • patients on chronic immunosuppressive transplant therapy
  • ICDs implanted less than 6 months prior to cellular implantation procedure. ICDs reprogrammed during the course of treatment and stable for less than 3 months. Patients fitted w/a Bi-V pacer are excluded.
  • patients who, in the opinion of the investigator, are not suitable to participate, following review of the catheter information in appendix IV

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Overall Objective
To assess the effect and safety of MyoCell™ therapy on myocardial function in congestive heart failure patients, post-myocardial infarction(s). Primary Safety Objective
The primary safety objective defined for this study is as follows:
The MyoCell™ implant will be considered safe if the number of serious adverse events at 3 months and 6 months is less than that seen in the control group (receiving standard medical therapy), and falling within levels set in the statistical analysis pla
Primary MyoCellTM Efficacy Objective
The primary efficacy objective of SEISMIC is to demonstrate the response to MyoCell™ implantation on the change in LVEF at 3 and 6 months by MUGA compared to baseline. Comparisons on LVEF will also be made between the two randomized groups (i.e. MyoCell

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bioheart, Inc.

Investigators

  • Principal Investigator: Jozef - Bartunek, MD, Cardiovascular Center, Aalst
  • Principal Investigator: Anthony - Gershlick, MD, Glenfield Hospital, University Hospitals of Leicester
  • Principal Investigator: Christoph - Hehrlein, MD, University of Freiburg
  • Principal Investigator: Carlos - Macaya, MD, Hospital Clinico San Carlos, Spain
  • Principal Investigator: Christoph - Nienaber, MD, University, Rostock, Germany
  • Principal Investigator: Nicholas - Peters, MD, St Mary's Hospital & Imperial College, London
  • Principal Investigator: Joachim - Schofer, MD, Universitaires Herzzentrum Hamburg, Germany
  • Study Chair: Patrick - Serruys, MD, Thorax Centre-Erasmus University, The Netherlands
  • Principal Investigator: Tomasz - Siminiak, MD, Cardiac & Rehabilitation Hospital at Kowanowko,Poland
  • Principal Investigator: Peter - Smits, MD, Medisch Centrum, Rijnmond Zuid, The Netherlands
  • Principal Investigator: J. - Waltenberger, MD, Academisch Ziekenhuis Maastrict, The Netherlands
  • Principal Investigator: Walter Van Mieghem, MD, ZOL Campus St. Jan, Genk, Belgium
  • Principal Investigator: Victor Legrand, MD, University Hospital, Liege, Belgium

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2005

Study Completion (Anticipated)

January 1, 2008

Study Registration Dates

First Submitted

September 11, 2006

First Submitted That Met QC Criteria

September 12, 2006

First Posted (Estimate)

September 13, 2006

Study Record Updates

Last Update Posted (Estimate)

October 12, 2007

Last Update Submitted That Met QC Criteria

October 11, 2007

Last Verified

October 1, 2007

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BMI-EU-02-008

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction

Clinical Trials on Myoblasts injection with MyoCath catheter

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe